Taurine Supplementation in Long COVID

Sponsor
University of Alberta
Study ID
NCT06721949
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Taurine — DRUG
    Taurine is a naturally occurring amino sulfonic acid commonly found in the body. It is marketed as a natural health product/supplement and plays an important role in the body.
  • Placebo — DRUG
    The placebo capsule is visually identical to the taurine capsule.

Study Details

The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19, has emerged as a complex multisystemic condition and challenging health issue, affecting approximately 10% of COVID-19 patients. Various symptoms characterize LC, including fatigue, sleep disturbances, cognitive impairment, and mood disturbances. Some of the symptoms are shared with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a condition marked by debilitating fatigue and a host of other symptoms without precise biomarkers or objective tests for diagnosis. Effective LC treatments remain elusive and LC patients continue to grapple with persistent symptoms that significantly impact their quality of life. Given the lack of effective treatments, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.

Key Dates

First listed
Dec 6, 2024
Start date
Nov 18, 2025
Status verified
May 2026
Primary completion
Feb 29, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Taurine
    Participants randomized to the Taurine arm will receive two 675 mg taurine capsules twice daily for 12 weeks.
  • Placebo Comparator: Placebo
    Participants randomized to the Placebo arm will receive two placebo capsules twice daily for 12 weeks. The placebo capsules will be visually identical to the taurine capsules.

Primary Outcome Measure

Mean change in Modified Fatigue Impact Scale (MFIS) from baseline to three months [ Time Frame: Three months ]

Central Contacts

Find similar trials

Nationwide
COVID-19 / long COVID trialsInfectious disease trials

Related Studies